Your session is about to expire
← Back to Search
Donor-Derived T-cell Therapy for HIV
Study Summary
This trial is testing a new HIV therapy that uses T-cells from a donor. The trial will study the safety and effectiveness of this new therapy in people who have had a bone marrow transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
How many participants are currently receiving treatment in this experiment?
"Affirmative. Data hosted on clinicaltrials.gov verifies that this research venture, which was first created on May 1st 2020, is actively recruiting participants. 8 people need to be sourced from two distinct medical centres."
Has the Drug and Food Administration sanctioned DD HST-NEETs for medical use?
"Our assessment at Power placed DD HST-NEETs on the lower end of safety, with a score of 1. This reflects this protocol's Phase 1 status, which suggests limited data to support both efficacy and security."
Are there any vacancies available for this research project?
"The clinical trial is open for enrollment, as attested to by the records on clinicaltrials.gov from its inception date of May 1st 2020 up until March 2nd 2022."
Share this study with friends
Copy Link
Messenger